National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Insulin aspart (NovoRapid® FlexTouch ®) is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

Rapid Review

Commenced Completed Outcome
22/07/2014 28/08/2014 Full pharmacoeconomic evaluation recommended at the submitted price.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.